ELDN Company Profile and Key Details

ELDN has shown mixed momentum, gaining 15.71% over the past week and -35.76% over the past quarter, though year-to-date performance is up 46.36%. Short-term trend indicators are mixed aligned (SMA20 10.88%, SMA50 23.32%, SMA200 -6.56%). The stock’s 14-day RSI is 64.83 (firm momentum), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.39% below its high and over 79.26% above its low. Average 10-day trading volume of 1.56 million shares is in line with the 3-month average of 1.55 million, indicating normal recent market interest.

Eledon Pharmaceuticals, Inc. has 59.88 million shares outstanding. The public float is 39.76 million shares, elevated short interest at 10.20% of float. This equals 5.46 million shares. The short ratio is 5.83 days. Institutional investors hold 73.28% of the float. Insiders own 1.4%. Harrison Seth Loring holds 7.91 million shares, Novartis Bioventures Ltd has 4.49 million shares and Apple Tree Partners II - Annex, L.P. has 3.57 million shares.

Eledon Pharmaceuticals, Inc. generated EPS of -$1.20 over the past year. Five-year average earnings growth is 50.24%. Wall Street analysts project EPS growth of -3.99% annually over the next five years. The latest quarter delivered EPS of -$18.25. The next quarter is forecast at -$0.20. Next year's EPS is expected at $26.04. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $8.00. The high target offers 210.88% upside. The low target suggests 107.25% downside. The mean target is $10.83. This offers 180.57% upside. Eledon Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by 8195.45%. The prior quarter beat by -50.0%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in March 20, 2025.

Eledon Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) closed at $3.86 USD, gaining $0.01 (0.26%) from the previous close of $3.85. The stock is currently mid-range between its 52-week high and low $1.35 and $4.60. With a market capitalization of about $231.40 million, Eledon Pharmaceuticals, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.96). Key stats such as the average daily volume over the past year has been around 1.57 million shares, volume is running light vs its 52-week average. Headquartered in Irvine, CA, Eledon Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David-Alexandre C. Gros, the company employs approximately 33 people and listed since September 17, 2014. Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) shares are up 46.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Eledon Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -4.39. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.73, suggesting 255.7% upside. Our AI forecast model points to short-term strength (7.25% over two weeks), a medium-term fall (-35.75% over three months), and a longer-term gain (371.24% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Eledon Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.25%, with price expected at $4.14 by July 27, 2026, within a range of $3.99 to $4.28 3-Month Outlook: Projected fall of -35.75%, reaching $2.48 by October 08, 2026, with a range of $2.22 to $2.66. 1-Year Outlook: Projected gain of 371.24%, with price at $18.19 by July 13, 2027, within a range of $3.90 to $31.17.

Eledon Pharmaceuticals, Inc. trades at a P/E ratio of -4.39, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.27 trading at moderately above to book value. The P/FCF stands at -3.32, also above market averages.